Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

February 3, 2022

Study Completion Date

March 5, 2022

Conditions
COVID-19SARS-CoV2 Infection
Interventions
BIOLOGICAL

IMMUNEPOTENT-CRP (I-CRP)

IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.

BIOLOGICAL

Placebo Comparator

The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).

Trial Locations (2)

64460

"Hospital Universitario Dr. Jose E. Gonzalez, Universidad Autonoma de Nuevo Leon", Monterrey

66450

Laboratorio de Inmunologia y Virologia, San Nicolás de los Garza

All Listed Sponsors
collaborator

Laboratorio de Inmunologia y Virologia - UANL

OTHER

collaborator

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

lead

Universidad Autonoma de Nuevo Leon

OTHER